Meglumine antimoniate

Meglumine antimoniate

Systematic (IUPAC) name
Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Identifiers
CAS Number	133-51-7
ATC code	P01CB01 (WHO) QP51AB01 (WHO)
PubChem	CID 64953
ChemSpider	58479
UNII	75G4TW236W
ChEMBL	CHEMBL239129
NIAID ChemDB	008733
Chemical data
Formula	Variable
Molar mass	Variable
SMILES O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
InChI InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M
(what is this?)  (verify)

Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.^[1] It is manufactured by Aventis^[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

See also

• Meglumine

References

1. Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical Infectious Diseases 26 (1): 56–58. doi:10.1086/516267. PMID 9455509.
2. Aventis press release, 15 April 2005. (German)